Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market

Fineline Cube Mar 27, 2026
Company Deals

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Fineline Cube Mar 26, 2026
Company Deals

MSD to Acquire Terns Pharmaceuticals for $6.7 Billion – TERN-701 BCR::ABL1 Inhibitor Targets Chronic Myeloid Leukemia

Fineline Cube Mar 26, 2026
Company Deals

Daiichi Sankyo Partners with Tempus AI – Foundation Models Target ADC Biomarker Discovery and Patient Stratification

Fineline Cube Mar 26, 2026
Company Deals

Thermo Fisher Partners with SHL Medical – Autoinjector Manufacturing Expansion Targets U.S. Drug-Device Combination Market

Fineline Cube Mar 26, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes

Fineline Cube Mar 27, 2026
Company Drug

Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction

Fineline Cube Mar 27, 2026
Policy / Regulatory

GSK’s Avodart Receives NMPA Approval to Resume Sales in China from September

Fineline Cube Feb 19, 2024

The National Medical Products Administration (NMPA) has released a notification announcing that GlaxoSmithKline’s (GSK) Avodart...

Policy / Regulatory

National Health Commission Notification Signals New Poliovirus Containment Measures

Fineline Cube Feb 19, 2024

The National Health Commission (NHC) has issued a notification announcing the establishment of the National...

Policy / Regulatory

China’s NHC Approves 2023 Large Medical Equipment Configuration Licenses, Targets Cancer Treatment

Fineline Cube Feb 19, 2024

The National Health Commission (NHC) has granted approval for the Class A large medical equipment...

Company Drug

Hainan Poly Pharm Wins FDA Nod for Generic Version of UCB’s Vimpat

Fineline Cube Feb 19, 2024

Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...

Company Policy / Regulatory

US Lawmakers Call for Sanctions Against WuXi AppTec and WuXi Biologics Over National Security Concerns

Fineline Cube Feb 19, 2024

US politicians have intensified their opposition to China’s biotech industry, with Congressmen and Senators sending...

Company

Novartis Begins Review of 70% Stake in Indian Unit, Strategic Options Under Consideration

Fineline Cube Feb 18, 2024

Novartis (NYSE: NVS) has initiated a review process concerning its 70.68% stake in Novartis India...

Company Medical Device

Boao Yiling Life Care Center Launches Innovative Dental Technologies Under Pilot Medical Policy

Fineline Cube Feb 18, 2024

Boao Yiling Life Care Center has successfully completed the inaugural use of a dental comprehensive...

Company Deals

Brii Biosciences Acquires VBI Vaccines’ Intellectual Property and Manufacturing Rights in Strategic Deal

Fineline Cube Feb 18, 2024

Brii Biosciences Ltd (HKG: 2137), based in China, has reached an agreement with US-based VBI...

Company

LianBio to Wind Down Operations Amid Market Challenges, Announces Special Dividend

Fineline Cube Feb 18, 2024

LianBio (OTCMKTS: LIANY), one of China’s prominent biotechnology firms, has announced plans to wind down...

Policy / Regulatory

NMPA Launches Pilot Program to Streamline Supplementary Drug Approval Process

Fineline Cube Feb 18, 2024

The National Medical Products Administration (NMPA) has unveiled the “Pilot Work Plan for Optimizing the...

Company

Organon Reports Q4 2023 Revenue Growth Driven by Women’s Health and Biosimilars

Fineline Cube Feb 18, 2024

Organon (NYSE: OGN), the U.S.-based pharmaceutical company, has reported its fourth-quarter 2023 financial results, revealing...

Company Drug

Roche’s Xolair Gains FDA Approval to Combat IgE-Mediated Food Allergies in Patients Aged 1 and Up

Fineline Cube Feb 18, 2024

Roche (SWX: ROG) has announced that the U.S. Food and Drug Administration (FDA) has granted...

Company Drug

Ipsen Secures FDA Approval for Onivyde Regimen as First-Line Treatment for Metastatic Pancreatic Adenocarcinoma

Fineline Cube Feb 18, 2024

Ipsen (EPA: IPN, OTCMKTS: IPSEY), the France-based biopharmaceutical company, has announced that the U.S. Food...

Company Drug

FDA Approves Takeda’s Eohilia as First Oral Therapy for Eosinophilic Esophagitis in Patients Aged 11 and Up

Fineline Cube Feb 18, 2024

The U.S. Food and Drug Administration (FDA) has granted approval to Takeda Pharmaceutical Company (TYO:...

Company Drug

Roche’s Piasky (Crovalimab) Secures NMPA Approval for Untreated Paroxysmal Nocturnal Hemoglobinuria

Fineline Cube Feb 9, 2024

The National Medical Products Administration (NMPA) has granted marketing approval to Swiss pharmaceutical giant Roche...

Company Drug

Roche Secures NMPA Approval for Rozlytrek to Treat Pediatric NTRK Fusion-Positive Tumors

Fineline Cube Feb 9, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has received a new indication approval from the National...

Company Deals

Akeso Biopharma to Acquire 35% Stake in AD Pharmaceuticals for RMB 267 Million

Fineline Cube Feb 9, 2024

Akeso Biopharma (HKG: 9926) is poised to acquire a 35% stake in AD Pharmaceuticals Co.,...

Company

AstraZeneca Reports 6% Revenue Growth in 2023, Driven by Oncology and Diabetes Drug Sales

Fineline Cube Feb 9, 2024

AstraZeneca (AZ; NASDAQ: AZN), the UK-based multinational, reported its financial results for 2023 this week,...

Company Deals

I-Mab to Become U.S.-Based Biotech, Divesting All China Assets for Up to $80 Million

Fineline Cube Feb 8, 2024

I-Mab (NASDAQ: IMAB), a biotech company transitioning to a U.S.-based entity, has announced plans to...

Company Deals

AbbVie Expands Licensing Agreement for Innovative sCAR-T Platform with Scripps Research

Fineline Cube Feb 8, 2024

AbbVie (NYSE: ABBV) has expanded its collaboration with Scripps Research’s Calibr-Skaggs Institute, securing licensing rights...

Posts pagination

1 … 377 378 379 … 642

Recent updates

  • C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market
  • Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes
  • Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction
  • CStone Pharma 2025 Revenue RMB 269.6M Down 34% – NRDL Price Adjustment Hits Pralsetinib, Licensing Fees Decline
  • Chengdu Kanghong’s KHN922 Wins NMPA Approval – Dual-Payload HER3 ADC Targets Advanced Solid Tumors with Anti-Resistance Mechanism
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market

Company Drug

Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes

Company Drug

Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction

Company

CStone Pharma 2025 Revenue RMB 269.6M Down 34% – NRDL Price Adjustment Hits Pralsetinib, Licensing Fees Decline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.